Insider Buying: CVS Health (NYSE:CVS) EVP Acquires 23,855 Shares of Stock

Key Points

• CVS EVP Prem Shah bought 23,855 shares for about $2.0 million at an average price of $83.89, increasing his direct ownership by 36.89% to 88,516 shares.
• CVS beat third-quarter earnings and revenue expectations, reporting EPS of $2.09 versus analysts’ $1.65 estimate and revenue of $108.4 billion; revenue rose 5.4% year over year.
• Investors are weighing the stronger results and raised outlook against uncertainty over CVS’s planned 2028 separation, including unanswered questions about its structure and costs. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $108.25.

CVS Health Corporation (NYSE:CVS - Get Free Report) EVP Prem Shah bought 23,855 shares of the business's stock in a transaction dated Friday, November 6th. The stock was acquired at an average price of $83.89 per share, for a total transaction of $2,001,195.95. Following the purchase, the executive vice president directly owned 88,516 shares in the company, valued at approximately $7,425,607.24. The trade was a 36.89% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

CVS Health Stock Performance

Shares of CVS stock traded up $2.43 during trading on Friday, hitting $83.76. The company's stock had a trading volume of 14,033,340 shares, compared to its average volume of 8,542,881. The company has a market cap of $107.12 billion, a PE ratio of 9.75, a P/E/G ratio of 0.73 and a beta of 0.58. The company has a current ratio of 0.85, a quick ratio of 0.66 and a debt-to-equity ratio of 0.71. The business has a fifty day moving average of $90.56 and a 200-day moving average of $88.87. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, topping analysts' consensus estimates of $1.65 by $0.44. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The business had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. During the same period last year, the company posted $1.60 earnings per share. CVS Health's quarterly revenue was up 5.4% compared to the same quarter last year. As a group, research analysts anticipate that CVS Health Corporation will post 8.20 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd were given a $0.6650 dividend. The ex-dividend date of this dividend was Thursday, October 22nd. This represents a $2.66 annualized dividend and a yield of 3.2%. CVS Health's payout ratio is currently 30.97%.

Analyst Ratings Changes

Several brokerages have recently issued reports on CVS. Piper Sandler set a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Argus upped their price objective on CVS Health from $104.00 to $114.00 and gave the company a "buy" rating in a research note on Wednesday, August 19th. Cantor Fitzgerald reissued a "neutral" rating on shares of CVS Health in a report on Friday, October 9th. Raymond James Financial set a $103.00 target price on CVS Health in a research report on Friday. Finally, Evercore restated an "outperform" rating on shares of CVS Health in a research note on Wednesday. Twenty-two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $108.25.

Hedge Funds Weigh In On CVS Health

Large investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in CVS Health in the second quarter worth $12,747,462,000. State Street Corp increased its holdings in shares of CVS Health by 26.3% during the second quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator's stock valued at $7,751,205,000 after acquiring an additional 15,604,883 shares in the last quarter. Wellington Management Group LLP raised its position in shares of CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator's stock worth $3,496,725,000 after purchasing an additional 11,233,381 shares during the last quarter. Bank of America Corp DE raised its position in shares of CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock worth $2,398,868,000 after purchasing an additional 13,836,701 shares during the last quarter. Finally, Pzena Investment Management LLC bought a new position in CVS Health in the 2nd quarter worth about $1,217,558,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS beat third-quarter earnings and revenue expectations and raised its 2026 outlook, with management citing improvement at Aetna. These stronger fundamentals offer support for the shares. CVS Health Q3 Earnings Call Focuses on Planned Pharmacy Separation
• Positive Sentiment: The planned separation, targeted for 2028, could let investors value the retail pharmacy business and the insurance/health-services businesses separately. Some investors see potential for the move to unlock value, although the outcome depends on the details. CVS Health: The Breakup Puts A Price On The Pharmacy
• Neutral Sentiment: UBS and Leerink lowered their price targets but kept Buy/Outperform ratings, while Barclays also trimmed its target and maintained an Overweight rating—suggesting continued optimism alongside more cautious valuation assumptions. UBS price-target update
• Negative Sentiment: The breakup announcement triggered a sharp selloff in recent trading, as CVS has not yet provided key details on structure, costs, or how the businesses will operate separately. That uncertainty has overshadowed the earnings beat and may keep pressure on the stock until investors can assess the plan. Why CVS stock fell after raising its outlook and announcing a breakup
• Negative Sentiment: Reports that CVS lost ground on Medicare ratings raise concern about Aetna’s competitive position and potential effects on its Medicare business. Separately, AM Best placed ratings for Aetna subsidiaries under review with developing implications amid the planned separation, adding to uncertainty. CVS and UnitedHealth lost ground on Medicare ratings

CVS Health Company Profile

CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division.

The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.

Founded in 1963 as Consumer Value Stores in Lowell, Massachusetts, the company expanded from a retail pharmacy business into a broad health care organization and adopted the CVS Health name in 2014.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.